Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 63

1.

Switching to raltegravir in virologically suppressed in HIV-1-infected patients: a retrospective, multicenter, descriptive study.

Podzamczer D, Martínez E, Domingo P, Ferrer E, Viciana P, Curto J, Pérez-Elías MJ, Ocampo A, Santos I, Knobel H, Estrada V, Negredo E, Segura F, Portilla J, Ribera E, Galindo J, Antela A, Carmena J, Castaño M, The Toral Study Group.

Curr HIV Res. 2012 Dec;10(8):673-8.

PMID:
23061598
2.

Nevirapine-raltegravir combination, an NRTI and PI/r sparing regimen, as maintenance antiretroviral therapy in virologically suppressed HIV-1-infected patients.

Reliquet V, Chirouze C, Allavena C, Muret P, Peytavin G, André-Garnier E, Bettinger D, Ferré V, Hoen B, Raffi F.

Antivir Ther. 2014;19(1):117-23. doi: 10.3851/IMP2691. Epub 2013 Oct 22.

PMID:
24145365
3.

Substitution of raltegravir for ritonavir-boosted protease inhibitors in HIV-infected patients: the SPIRAL study.

Martínez E, Larrousse M, Llibre JM, Gutiérrez F, Saumoy M, Antela A, Knobel H, Murillas J, Berenguer J, Pich J, Pérez I, Gatell JM; SPIRAL Study Group.

AIDS. 2010 Jul 17;24(11):1697-707. doi: 10.1097/QAD.0b013e32833a608a. Erratum in: AIDS. 2010 Oct 23;24(16):2602.

PMID:
20467288
4.

Switch to raltegravir decreases soluble CD14 in virologically suppressed overweight women: the Women, Integrase and Fat Accumulation Trial.

Lake JE, McComsey GA, Hulgan T, Wanke CA, Mangili A, Walmsley SL, Stramotas SA, Tracy R, Currier JS.

HIV Med. 2014 Aug;15(7):431-41. doi: 10.1111/hiv.12128. Epub 2014 Feb 10.

5.

Efficacy and safety of raltegravir in treatment-experienced HIV-1-infected patients switching from enfuvirtide-based regimens: 48 week results of the randomized EASIER ANRS 138 trial.

Gallien S, Braun J, Delaugerre C, Charreau I, Reynes J, Jeanblanc F, Verdon R, de Truchis P, May T, Madelaine-Chambrin I, Aboulker JP, Molina JM; EASIER ANRS 138 Study Group.

J Antimicrob Chemother. 2011 Sep;66(9):2099-106. doi: 10.1093/jac/dkr269. Epub 2011 Jun 28.

6.

Dual raltegravir/etravirine combination in virologically suppressed HIV-1-infected patients on antiretroviral therapy.

Calin R, Paris L, Simon A, Peytavin G, Wirden M, Schneider L, Valantin MA, Tubiana R, Agher R, Katlama C.

Antivir Ther. 2012;17(8):1601-4. doi: 10.3851/IMP2344. Epub 2012 Sep 3.

PMID:
22941896
7.

96 Week follow-up of HIV-infected patients in rescue with raltegravir plus optimized backbone regimens: a multicentre Italian experience.

Capetti A, Landonio S, Meraviglia P, Di Biagio A, Lo Caputo S, Sterrantino G, Ammassari A, Menzaghi B, Franzetti M, De Socio GV, Pellicanò G, Mazzotta E, Soria A, Meschiari M, Trezzi M, Sasset L, Celesia BM, Zucchi P, Melzi S, Ricci E, Rizzardini G.

PLoS One. 2012;7(7):e39222. doi: 10.1371/journal.pone.0039222. Epub 2012 Jul 11.

8.

Raltegravir as functional monotherapy leads to virological failure and drug resistance in highly treatment-experienced HIV-infected patients.

Caby F, Valin N, Marcelin AG, Schneider L, Andrade R, Guiguet M, Tubiana R, Canestri A, Valantin MA, Peytavin G, Pacanowski J, Morand-Joubert L, Calvez V, Girard PM, Katlama C.

Scand J Infect Dis. 2010 Jul;42(6-7):527-32. doi: 10.3109/00365541003621502.

PMID:
20222846
9.

Dynamics of HIV-1 DNA level in highly antiretroviral-experienced patients receiving raltegravir-based therapy.

Charpentier C, Piketty C, Laureillard D, Tisserand P, Si-Mohamed A, Weiss L, Bélec L.

Eur J Clin Microbiol Infect Dis. 2012 Feb;31(2):129-33. doi: 10.1007/s10096-011-1284-0. Epub 2011 May 11.

PMID:
21559766
10.

Short communication: Effectiveness at 48 weeks of switching from enfuvirtide to raltegravir in virologically suppressed multidrug-resistant HIV type 1-infected patients in a Brazilian cohort.

Westin MR, Biscione F, Ribeiro KM, Greco DB, Tupinambás U.

AIDS Res Hum Retroviruses. 2014 Feb;30(2):113-7. doi: 10.1089/AID.2013.0084. Epub 2013 Aug 14.

PMID:
23875625
11.

Safety and effectiveness of raltegravir in patients with haemophilia and anti-HIV multidrug resistance.

Mangiafico L, Perja M, Fusco F, Riva S, Mago D, Gringeri A.

Haemophilia. 2012 Jan;18(1):108-11. doi: 10.1111/j.1365-2516.2011.02610.x. Epub 2011 Jul 18.

PMID:
21762404
12.

Dynamic patterns of human immunodeficiency virus type 1 integrase gene evolution in patients failing raltegravir-based salvage therapies.

Canducci F, Sampaolo M, Marinozzi MC, Boeri E, Spagnuolo V, Galli A, Castagna A, Lazzarin A, Clementi M, Gianotti N.

AIDS. 2009 Feb 20;23(4):455-60. doi: 10.1097/QAD.0b013e328323da60.

PMID:
19165083
13.

Drug resistance profiles for the HIV integrase gene in patients failing raltegravir salvage therapy.

Charpentier C, Karmochkine M, Laureillard D, Tisserand P, Bélec L, Weiss L, Si-Mohamed A, Piketty C.

HIV Med. 2008 Oct;9(9):765-70. doi: 10.1111/j.1468-1293.2008.00628.x. Epub 2008 Jul 21.

14.

HIV-1 resistance patterns to integrase inhibitors in antiretroviral-experienced patients with virological failure on raltegravir-containing regimens.

da Silva D, Van Wesenbeeck L, Breilh D, Reigadas S, Anies G, Van Baelen K, Morlat P, Neau D, Dupon M, Wittkop L, Fleury H, Masquelier B.

J Antimicrob Chemother. 2010 Jun;65(6):1262-9. doi: 10.1093/jac/dkq099. Epub 2010 Apr 12.

15.

No evidence of autoimmune disorders in antiretroviral-experienced HIV-1-infected individuals after long-term treatment with raltegravir.

Baroncelli S, Mezzaroma I, Fantauzzi A, Galluzzo CM, Antoni AD, Vullo V, Francisci D, Ladisa N, Vivarelli A, Cirioni O, Sighinolfi L, Weimer LE, Fragola V, Fidanza R, Cara A, Palmisano L.

Antivir Ther. 2013;18(3):321-7. doi: 10.3851/IMP2433. Epub 2012 Oct 9.

PMID:
23047152
16.

Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection.

Cooper DA, Steigbigel RT, Gatell JM, Rockstroh JK, Katlama C, Yeni P, Lazzarin A, Clotet B, Kumar PN, Eron JE, Schechter M, Markowitz M, Loutfy MR, Lennox JL, Zhao J, Chen J, Ryan DM, Rhodes RR, Killar JA, Gilde LR, Strohmaier KM, Meibohm AR, Miller MD, Hazuda DJ, Nessly ML, DiNubile MJ, Isaacs RD, Teppler H, Nguyen BY; BENCHMRK Study Teams.

N Engl J Med. 2008 Jul 24;359(4):355-65. doi: 10.1056/NEJMoa0708978.

17.

Virological and immunological response in HIV-1-infected patients with multiple treatment failures receiving raltegravir and optimized background therapy, ANRS CO3 Aquitaine Cohort.

Wittkop L, Breilh D, Da Silva D, Duffau P, Mercié P, Raymond I, Anies G, Fleury H, Saux MC, Dabis F, Fagard C, Thiébaut R, Masquelier B, Pellegrin I; ANRS CO3 Aquitaine Cohort.

J Antimicrob Chemother. 2009 Jun;63(6):1251-5. doi: 10.1093/jac/dkp114. Epub 2009 Mar 31.

18.

Rapid and durable antiretroviral effect of the HIV-1 Integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled study.

Markowitz M, Nguyen BY, Gotuzzo E, Mendo F, Ratanasuwan W, Kovacs C, Prada G, Morales-Ramirez JO, Crumpacker CS, Isaacs RD, Gilde LR, Wan H, Miller MD, Wenning LA, Teppler H; Protocol 004 Part II Study Team.

J Acquir Immune Defic Syndr. 2007 Oct 1;46(2):125-33.

PMID:
17721395
19.

Raltegravir with optimized background therapy for resistant HIV-1 infection.

Steigbigel RT, Cooper DA, Kumar PN, Eron JE, Schechter M, Markowitz M, Loutfy MR, Lennox JL, Gatell JM, Rockstroh JK, Katlama C, Yeni P, Lazzarin A, Clotet B, Zhao J, Chen J, Ryan DM, Rhodes RR, Killar JA, Gilde LR, Strohmaier KM, Meibohm AR, Miller MD, Hazuda DJ, Nessly ML, DiNubile MJ, Isaacs RD, Nguyen BY, Teppler H; BENCHMRK Study Teams.

N Engl J Med. 2008 Jul 24;359(4):339-54. doi: 10.1056/NEJMoa0708975.

20.

Potent and sustained antiviral response of raltegravir-based highly active antiretroviral therapy in HIV type 1-infected children and adolescents.

Briz V, León-Leal JA, Palladino C, Moreno-Perez D, de Ory SJ, De José MI, González-Tomé MI, Martín CG, Pocheville I, Ramos JT, Leal M, Muñoz-Fernández MÁ.

Pediatr Infect Dis J. 2012 Mar;31(3):273-7. doi: 10.1097/INF.0b013e31824580e8.

PMID:
22330165
Items per page

Supplemental Content

Write to the Help Desk